{"id":970449,"date":"2026-06-04T06:34:38","date_gmt":"2026-06-04T10:34:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/"},"modified":"2026-06-04T06:34:38","modified_gmt":"2026-06-04T10:34:38","slug":"bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/","title":{"rendered":"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>New integrated workflow combines icIEF fractionation and mass photometry<\/li>\n<li>Enables direct characterization of aggregation and size within\u00a0icIEF-resolved charge variants<\/li>\n<li>Four-hour workflow reduces development risk and accelerates biosimilar manufacturing<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\">MINNEAPOLIS and OXFORD, England<\/span>, <span class=\"legendSpanClass\">June 4, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0Bio\u2011Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first\u2011of\u2011its\u2011kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.<\/p>\n<p>By combining <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=552222038&amp;u=https%3A%2F%2Fwww.bio-techne.com%2Finstruments%2Fice%2Fmauriceflex&amp;a=R%26D+Systems+MauriceFlex%E2%84%A2\" target=\"_blank\" rel=\"nofollow\">R&amp;D Systems MauriceFlex\u2122<\/a> imaged capillary isoelectric focusing (icIEF) fractionation system with <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=1067976142&amp;u=https%3A%2F%2Frefeyn.com%2Ftwomp&amp;a=Refeyn%27s+TwoMP+mass+photometry+platform\" target=\"_blank\" rel=\"nofollow\">Refeyn&#8217;s TwoMP mass photometry platform<\/a>, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single\u2011molecule resolution in a streamlined four\u2011hour workflow.<\/p>\n<p>Bispecific antibodies are among the fastest-growing classes of biotherapeutics, but their structural complexity makes thorough characterization challenging. Incomplete characterization can delay development, increase manufacturing risk, and lead to costly late\u2011stage failures.<\/p>\n<p>The MauriceFlex\u2122 system delivers high-resolution separation and fractionation of charge variants, a capability increasingly expected in regulatory submissions. However, analyzing the size and aggregation of individual charge fractions has historically been difficult due to the large sample requirements of traditional methods.<\/p>\n<p>The integrated workflow addresses this challenge directly by pairing icIEF fractionation with mass photometry. Charge variants are first separated using MauriceFlex\u2122, then analyzed on Refeyn&#8217;s TwoMP platform, which requires only nanogram\u2011level sample and reveals size distribution and aggregation at single\u2011molecule resolution.<\/p>\n<p>Together, the technologies enable direct characterization of aggregation and size within\u00a0icIEF-resolved charge variants\u2014an insight not accessible with standalone methods\u2014reducing reliance on multiple tests and enabling faster, more efficient process development.<\/p>\n<p>&#8220;Bispecifics are the fastest growing segment within next\u2011generation antibodies, but they are very difficult to characterize. This approach directly addresses one of the biggest challenges by combining icIEF fractionation with mass photometry. Researchers can now interrogate charge and size variants together in a single workflow,&#8221; said Gerry Mackay, CEO of Refeyn.<\/p>\n<p>&#8220;Our customers are under intense pressure to develop and manufacture increasingly complex biologics faster and more efficiently. Enabling deeper characterization with less sample helps them reduce risk, control costs, and make better decisions earlier in development,&#8221; said Will Geist, President Bio\u2011Techne Protein Sciences Segment.<\/p>\n<p>In a joint <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=307563118&amp;u=https%3A%2F%2Fwww.bio-techne.com%2Fresources%2Fwebinars%2Fmauriceflex-mp&amp;a=webinar\" target=\"_blank\" rel=\"nofollow\">webinar<\/a>, scientists demonstrated the workflow using Mosunetuzumab\u2011axgb and a biosimilar, tracking size-related changes in the molecule across charge variant fractions under multiple conditions. An application note with full findings is available <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=3325703979&amp;u=https%3A%2F%2Fresources.rndsystems.com%2Finstruments%2Fcapillary-electrophoresis%2Fmauriceflex-mass-photometry-app-note.pdf&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a>.<\/p>\n<p>The workflow will also be presented at the American Society for Mass Spectrometry (ASMS) conference, taking place May 31 \u2013 June 4, 2026, in San Diego. See booth and poster details <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=1185551408&amp;u=https%3A%2F%2Fresources.rndsystems.com%2Fpdfs%2Fdocuments%2Fasms-conference-schedule.pdf&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a><\/p>\n<p>\n        <b>ABOUT BIO<\/b>\u2011<b>TECHNE<\/b><\/p>\n<p>Bio\u2011Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high\u2011quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer\u2011focused brands: R&amp;D Systems\u2122, Bio\u2011Techne Spatial\u2122, and Bio\u2011Techne Diagnostics\u2122, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio\u2011Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.<\/p>\n<p>For more information on Bio\u2011Techne, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=2336251044&amp;u=https%3A%2F%2Fwww.bio-techne.com%2F&amp;a=www.bio-techne.com\" target=\"_blank\" rel=\"nofollow\">www.bio-techne.com<\/a> or follow the company on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=4282715768&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbio-techne%2Fposts%2F%3FfeedView%3Dall&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=3100691164&amp;u=https%3A%2F%2Fx.com%2Fbiotechne&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>, or <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=919451089&amp;u=https%3A%2F%2Fwww.youtube.com%2F%40Bio-Techne%2Fvideos&amp;a=YouTube\" target=\"_blank\" rel=\"nofollow\">YouTube<\/a>.<\/p>\n<p>\n        <b>ABOUT REFEYN<\/b>\n      <\/p>\n<p>Refeyn specializes in the development, production, and distribution of mass photometry solutions for industry and academia. Its innovative technology enables accurate mass measurement of single molecules in their native state without labels, delivering faster insights with minimal sample compared to conventional methods.<\/p>\n<p>For more information on Refeyn, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=1526189207&amp;u=https%3A%2F%2Frefeyn.com%2F&amp;a=www.refeyn.com\" target=\"_blank\" rel=\"nofollow\">www.refeyn.com<\/a> or follow the company on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=2379280832&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Frefeyn%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a> or <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703619-1&amp;h=3460229346&amp;u=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUC8_box5uaget2X1GJcLR7XA&amp;a=YouTube\" target=\"_blank\" rel=\"nofollow\">YouTube<\/a>.<\/p>\n<p>\n        <b>MEDIA CONTACTS:<\/b>\n      <\/p>\n<p>\n        <b>Bio<\/b>\u2011<b>Techne<\/b><br \/>David Clair, Vice President Investor Relations<br \/><a href=\"mailto:IR@bio-techne.com\" target=\"_blank\" rel=\"nofollow\">IR@bio-techne.com<\/a>\u00a0<\/p>\n<p>Corporate Communications<br \/><a href=\"mailto:media.relations@bio-techne.com\" target=\"_blank\" rel=\"nofollow\">media.relations@bio-techne.com<\/a>\u00a0<\/p>\n<p>\n        <b>Refeyn<\/b><br \/>\n        <br \/>Catie Lichten<br \/>Scientific Communications Manager<br \/><a href=\"mailto:catie.lichten@refeyn.com\" target=\"_blank\" rel=\"nofollow\">catie.lichten@refeyn.com<\/a>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3429\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661\" title=\"\" alt=\"\" \/>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG75452&amp;sd=2026-06-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/biotechne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization-302791071.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/biotechne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization-302791071.html<\/a><\/p>\n<p>SOURCE Bio-Techne Corporation<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG75452&amp;Transmission_Id=202606040630PR_NEWS_USPR_____CG75452&amp;DateId=20260604\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within\u00a0icIEF-resolved charge variants Four-hour workflow reduces development risk and accelerates biosimilar manufacturing MINNEAPOLIS and OXFORD, England, June 4, 2026 \/PRNewswire\/ &#8212;\u00a0Bio\u2011Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first\u2011of\u2011its\u2011kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars. By combining R&amp;D Systems MauriceFlex\u2122 imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn&#8217;s TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single\u2011molecule resolution in a streamlined four\u2011hour workflow. Bispecific antibodies are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970449","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within\u00a0icIEF-resolved charge variants Four-hour workflow reduces development risk and accelerates biosimilar manufacturing MINNEAPOLIS and OXFORD, England, June 4, 2026 \/PRNewswire\/ &#8212;\u00a0Bio\u2011Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first\u2011of\u2011its\u2011kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars. By combining R&amp;D Systems MauriceFlex\u2122 imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn&#8217;s TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single\u2011molecule resolution in a streamlined four\u2011hour workflow. Bispecific antibodies are &hellip; Continue reading &quot;Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T10:34:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization\",\"datePublished\":\"2026-06-04T10:34:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/\"},\"wordCount\":686,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1854744\\\/Bio-Techne-Refeyn_4.jpg?id=OA2656661\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/\",\"name\":\"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1854744\\\/Bio-Techne-Refeyn_4.jpg?id=OA2656661\",\"datePublished\":\"2026-06-04T10:34:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1854744\\\/Bio-Techne-Refeyn_4.jpg?id=OA2656661\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1854744\\\/Bio-Techne-Refeyn_4.jpg?id=OA2656661\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/","og_locale":"en_US","og_type":"article","og_title":"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Market Newsdesk","og_description":"PR Newswire New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within\u00a0icIEF-resolved charge variants Four-hour workflow reduces development risk and accelerates biosimilar manufacturing MINNEAPOLIS and OXFORD, England, June 4, 2026 \/PRNewswire\/ &#8212;\u00a0Bio\u2011Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first\u2011of\u2011its\u2011kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars. By combining R&amp;D Systems MauriceFlex\u2122 imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn&#8217;s TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single\u2011molecule resolution in a streamlined four\u2011hour workflow. Bispecific antibodies are &hellip; Continue reading \"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-04T10:34:38+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization","datePublished":"2026-06-04T10:34:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/"},"wordCount":686,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/","name":"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661","datePublished":"2026-06-04T10:34:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1854744\/Bio-Techne-Refeyn_4.jpg?id=OA2656661"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bio\u2011Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970449"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970449\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}